Comparing Low-Dose and Standard-Dose Rivaroxaban for Treating Atrial Fibrillation in Patients Aged 70 and Older
Led by China National Center for Cardiovascular Diseases · Updated on 2024-09-19
4374
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation. This Phase 4 randomized study focuses on patients aged 70 years and older who have atrial fibrillation and a CHA2DS2-VASc score indicating moderate to high stroke risk. The goal is to compare these dosing strategies to better understand their impact on cardiovascular and cerebrovascular events.
Participants are randomly assigned to one of two groups the low-dose group receives 15 mg of rivaroxaban daily, which may be reduced to 10 mg daily for certain conditions such as reduced kidney function, low body weight, or age 80 and above the standard-dose group receives 20 mg daily, with dose reductions to 15 mg under the same conditions. Treatment lasts for approximately two years following randomization, with adherence to dosing guidelines based on individual health factors.
During the study, participants will be monitored for major adverse cardiovascular and cerebrovascular events over about two years. Researchers will also track bleeding events, overall clinical benefits, and other related health outcomes. Assessments include regular clinical evaluations, safety monitoring, and follow-up visits to ensure patient well-being and gather data on the effects of both dosing regimens throughout the study period.
CONDITIONS
Brief Title
Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
Research Team
Z
Zhe Zheng, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of atrial fibrillation with rhythm lasting at least 30 seconds recorded by ECG or Holter within 1 year
CHA2DS2-VASc score of 2 or higher for men and 3 or higher for women
Ability to cooperate and sign informed consent forms
You will not qualify if you...
Moderate-to-severe mitral stenosis, prior mechanical valve replacement, unresected atrial myxoma, or known left ventricular thrombus
Biological valve replacement or valve repair surgery within 6 months
Left ventricular assist device implantation
Severe stroke event within 3 months or any stroke within 14 days
Transient ischemic attack within 3 days
Transient atrial fibrillation due to reversible triggers
Planned or prior atrial fibrillation catheter ablation, drug cardioversion, electroconversion, or major surgery within 3 months
Prior or planned left atrial appendage occlusion
Active infective endocarditis
High or increasing bleeding risk including recent traumatic surgery, severe hemorrhages, gastrointestinal bleeding within past year, peptic ulcer within last month, bleeding disorders, or difficult-controlled hypertension
Severe renal impairment with creatinine clearance 15 mL/min or less
Active liver disease including persistent elevated liver enzymes, known hepatitis, or cirrhosis
Hemoglobin below 100g/L or low platelet count
Conditions requiring anticoagulation other than atrial fibrillation
Use of warfarin anticoagulation
Daily aspirin dose over 100mg
Recent dual antiplatelet or intravenous antiplatelet drug use within 5 days
Recent or planned fibrinolytic treatment
Use of certain interacting medications such as CYP3A4 and P-gp inhibitors, SSRIs, CYP3A4 inducers, or long-term NSAIDs
Allergic reactions to rivaroxaban ingredients
Recent malignant tumors or ongoing cancer treatment with limited life expectancy
Antiphospholipid syndrome
Participation in another clinical trial within past 30 days
Mental disorders or cognitive impairment affecting study participation
Known poor adherence to treatment or follow-up
Other conditions deemed unsuitable by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 2 years
Participants receive either low-dose or standard-dose rivaroxaban daily to reduce the risk of cardiovascular and cerebrovascular events.
Regular visits throughout the 2 years for treatment and monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study Evaluating Combined Cognitive and Balance Rehabilitation for Adults Recovering From Stroke
Using 320-Detector CT to Measure Heart Tissue Fibrosis in Adults with Atrial Fibrillation
Before Catheter Ablation Treatment
Using 5T MRI and Metabolomics to Predict Hemorrhage Risk in Moyamoya Disease A Prospective Observational Cohort Study
Testing Caregiver-Assisted Strategy Training to Improve Daily Activities for Adults After Stroke in a Multi-Center Trial
Stroke Recovery Study Using EEG-Guided Muscle and Tongue Stimulation
Evaluating Brain-Computer Interface and Functional Electric Stimulation Therapy
Digital Intervention to Improve Depression and Executive Function After Stroke Using AKL-T01 and Coaching
Smart Home-Based Upper Limb Rehabilitation Using Robot and Task Training for Adults with Stroke and Spinal Cord Injuries
Study of Brain Activity Using Functional Near-Infrared Spectroscopy in Stroke Patients During Mirror Movement
Using a Mobile BrainBody Imaging System to Improve Post-Stroke Walking with a Robotic Device
Study on Intravenous Thrombolysis Using Alteplase or Tenecteplase for Acute Ischemic Stroke Treated Between 4.5 and 24 Hours After Onset
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy and safety of low-dose rivaroxaban in elderly patients with atrial fibrillation for oral anticoagulation therapy: Rationale, design, and study protocol for a multicenter randomized controlled trial (SAFE-AF).